Home / Resource Library / A phase II study of daratumumab and ibrutinib for relapsed/refractory chronic lymphocytic leukemia

A phase II study of daratumumab and ibrutinib for relapsed/refractory chronic lymphocytic leukemia

Results of a study examining daratumumab with ibrutinib for treatment of relapsed CLL.